Guide price only. Final cost is confirmed after assessment.
nFat, or nano Fat, represents a breakthrough in regenerative medicine, offering a potent and targeted approach to treating osteoarthritis and other conditions. At London Cartilage Clinic, our nFat therapy uses finely processed adipose tissue, broken down into nano-scale particles to maximise surface area and regenerative potential.
Reviewed byProf Paul Lee MBBch, FRCS (Tr & Orth), PhDLast reviewed 1 May 2026
nFat is processed into very fine adipose-derived particles, creating a high-surface-area biological product designed for intensive cellular signalling.
Because nFat is highly refined and shorter-lived than other fat formats, it is typically prepared and delivered fresh for best effect.
Both options are autologous adipose-based therapies, but they are processed differently and may suit different treatment goals.
At consultation, we assess imaging, symptoms, and prior treatment response to select the most appropriate fat-based regenerative strategy.
While all these therapies utilise micro-fragmented adipose tissue, nFat is processed into even smaller pieces, providing a greater surface area for interaction and a more potent therapeutic effect, albeit with a shorter duration of efficacy.
nFat is primarily used in the treatment of osteoarthritis, offering relief from joint pain, aiding in cartilage repair, and improving overall joint function.
Due to its fine structure, nFat has a shorter half-life compared to other fat therapies, and is typically used in fresh preparations for optimal effectiveness.
Still have more specific concerns?
Free Discovery CallLondon Cartilage Clinic
Clinical updates, cartilage treatment guidance, and recovery-focused articles from our specialist team.
Hip cartilage lacks blood supply; once damaged, stress concentrates at the defect edge, widening the lesion in a self-reinforcing cycle that leads inevitably to bone-on-bone contact and osteoarthritis unless treated.
ChondroFiller is the same collagen scaffold in both the UK and Germany, but the UK delivers it as a 30–45-minute ultrasound-guided outpatient injection with same-day discharge, whilst Germany uses arthroscopic surgery under anaesthesia requiring post-operative immobilisation and months of physiotherapy.
ChondroFiller is an acellular collagen scaffold that recruits the patient's own progenitor cells to drive cartilage repair; suitability depends on three factors: damage grade, joint mechanics, and systemic health.
